Prosecution Insights
Last updated: November 04, 2026
Application No. 19/453,495

System and Method for Analysis of Endoscopic Imaging

Non-Final OA §102§112
Filed
Jan 20, 2026
Priority
Jan 19, 2025 — provisional 63/747,060
Examiner
PEHLKE, CAROLYN A
Art Unit
3793
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Vanquish Bio Inc.
OA Round
1 (Non-Final)
62%
Grant Probability
Moderate
1-2
OA Rounds
2y 7m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 62% of resolved cases
62%
Career Allowance Rate
310 granted / 499 resolved
-7.9% vs TC avg
Strong +28% interview lift
Without
With
+28.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
36 currently pending
Career history
542
Total Applications
across all art units

Statute-Specific Performance

§101
6.3%
-33.7% vs TC avg
§103
37.2%
-2.8% vs TC avg
§102
13.9%
-26.1% vs TC avg
§112
37.9%
-2.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 499 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119(e) as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Provisional Application No. 63/747,060, fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. The provisional application provides support only for “performing medical diagnostics on a patient’s pancreas further comprising determining, based on the AI processing and analysis of the EUS-images, a type of pancreatic focal lesions corresponding to the detected pancreatic lesions” (provisional claim 2) but does not provide support for any details of the independent claims including acquisition/receipt of at least gray-scale data and elastography data representing tissue stiffness, identifying a region of interest, segmenting the identified region from surrounding tissue, generating a characterization of the segmented region of interest using a plurality of imaging modalities including elastography, and generating a display with a graphical overlay. Therefore, the claimed invention is entitled only to the filing date of 01/20/2026. Drawings The drawings are objected to because figures 1 and 3 contain a substantial amount of text that is too small to be legibly reproduced and is entirely unreadable. Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Objections Claims 13-18 are objected to because of the following informalities: claim 13, and all dependent claims thereof, includes the text “Based on the provided excerpt from the patent application, here are several suggestions to improve clarity, completeness, and enforceability.” It appears that this text has been inserted into the claims in error. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 7-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 7 and 13, and all dependent claims thereof, recite a system and a method in the same claim (claims 7-12) or a product (CRM) and a method in the same claim (claims 13-18). A single claim which claims both an apparatus and the method steps of using the apparatus is indefinite under 35 U.S.C. 112(b) or pre-AIA 35 U.S.C. 112, second paragraph. See In re Katz Interactive Call Processing Patent Litigation, 639 F.3d 1303, 1318, 97 USPQ2d 1737, 1748-49 (Fed. Cir. 2011). See MPEP 2173.05(p)(II). Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-18 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Gheorghe et al. (WO 2024/180385 A1, Sep. 6, 2024) (hereinafter “Gheorghe”). Regarding claim 1: Gheorghe discloses a computer-implemented method for real-time analysis of pancreatic tissue (Artificial Intelligence and Machine Learning enabled systems and methods for detecting, marking, and differentiating pancreatic lesions and pancreatic parts from endoscopic images; Abstract), the method comprising: receiving, at a computing device (page 4, lines 104-107; FIG. 1), a real-time endoscopic ultrasound (EUS) video stream of a pancreas of a patient (page 24, lines 678-682), wherein the EUS video stream comprises a plurality of imaging modalities including at least grey-scale data (page 24, lines 678-682) and elastography data representing tissue stiffness (page 24, lines 678-682); processing, by one or more processors using an artificial intelligence (Al) model (page 25, lines 691-694), the EUS video stream to: identify a region of interest within the pancreas (page 22, lines 601-608); segment the identified region of interest from surrounding tissue (page 23, lines 647-652); and generate a characterization of the segmented region of interest based on an analysis of the plurality of imaging modalities (page 28, lines 782-786), including the elastography data (page 24, lines 678-682); and generating, for display on a user interface in real-time, a visual output comprising the EUS video stream with a graphical overlay (FIG. 16; page 22, lines 601-608), wherein the graphical overlay includes a visual indicator delineating the segmented region of interest and a classification label corresponding to the generated characterization (FIG. 16; page 22, lines 601-608). Regarding claim 2: Gheorghe discloses the method of claim 1, wherein the plurality of imaging modalities further comprises one or more of color doppler data (page 23, lines 635-642 and page 24, lines 678-682), contrast-enhanced arterial phase data, or contrast-enhanced venous phase data. Regarding claim 3: Gheorghe discloses the method of claim 1, wherein the classification label indicates that the segmented region of interest is one of a solid mass, a cystic lesion, or normal tissue (page 24, lines 674-677). Regarding claim 4: Gheorghe discloses the method of claim 1, wherein processing the EUS video stream by the Al model is performed on one or more remote servers in a cloud-computing environment, and wherein the computing device receives the visual output from the one or more remote servers (page 4, lines 104-107; page 13, lines 346-349; and page 20, lines 552-557 all refer to using remote cloud servers for storage and processing of data; FIG. 3 shows cloud 310 being used to process data in a loop which has output to AI Monitor 306; FIG. 8). Regarding claim 5: Gheorghe discloses the method of claim 1, further comprising: accessing a set of non-imaging patient data from an electronic medical record, the non-imaging patient data comprising at least one of laboratory test results, genomic data, or pathology reports (page 26, lines 725-726 describes using histopathology results); and wherein the Al model refines the characterization of the segmented region of interest based on the accessed non-imaging patient data (page 27, lines 745-748). Regarding claim 6: Gheorghe discloses the method of claim 1, further comprising generating, based on the characterization of the segmented region of interest, a recommendation for further procedures to be conducted on the segmented region of interest based on the characterization of the segmented region of interest (page 27, line 765 to page 28, line 781 describes using the method for determining feasibility of various treatment options). Regarding claim 7: Gheorghe discloses a system for real-time analysis of pancreatic tissue (Artificial Intelligence and Machine Learning enabled systems and methods for detecting, marking, and differentiating pancreatic lesions and pancreatic parts from endoscopic images; Abstract), the system comprising: one or more processors (page 4, lines 104-107; FIGS. 1 and 8); and a memory (page 4, lines 104-107; FIGS. 1 and 8) storing instructions that, when executed by the one or more processors, cause the system to perform a method comprising: receiving, at a computing device, a real-time endoscopic ultrasound (EUS) video stream of a pancreas of a patient (page 24, lines 678-682), wherein the EUS video stream comprises a plurality of imaging modalities including at least grey-scale data (page 24, lines 678-682) and elastography data representing tissue stiffness (page 24, lines 678-682); processing, by one or more processors using an artificial intelligence (Al) model (page 25, lines 691-694), the EUS video stream to: identify a region of interest within the pancreas (page 22, lines 601-608); segment the identified region of interest from surrounding tissue (page 23, lines 647-652); and generate a characterization of the segmented region of interest based on an analysis of the plurality of imaging modalities (page 28, lines 782-786), including the elastography data (page 24, lines 678-682); and generating, for display on a user interface in real-time, a visual output comprising the EUS video stream with a graphical overlay (FIG. 16; page 22, lines 601-608), wherein the graphical overlay includes a visual indicator delineating the segmented region of interest and a classification label corresponding to the generated characterization (FIG. 16; page 22, lines 601-608; page 23, lines 647 - 656). Regarding claim 8: Gheorghe discloses the system of claim 7, wherein the plurality of imaging modalities further comprises one or more of color doppler data (page 23, lines 635-642 and page 24, lines 678-682), contrast-enhanced arterial phase data, or contrast-enhanced venous phase data. Regarding claim 9: Gheorghe discloses the system of claim 7, wherein the classification label indicates that the segmented region of interest is one of a solid mass, a cystic lesion, or normal tissue (page 24, lines 674-677). Regarding claim 10: Gheorghe discloses the system or claim 7, wherein processing the EUS video stream by the Al model is performed on one or more remote servers in a cloud-computing environment, and wherein the computing device receives the visual output from the one or more remote servers (page 4, lines 104-107; page 13, lines 346-349; and page 20, lines 552-557 all refer to using remote cloud servers for storage and processing of data. FIG. 3 shows cloud 310 being used to process data in a loop which has output to AI Monitor 306; FIG. 8). Regarding claim 11: Gheorghe discloses the system of claim 7, wherein the method further comprises: accessing a set of non-imaging patient data from an electronic medical record, the non- imaging patient data comprising at least one of laboratory test results, genomic data, or pathology reports (page 26, lines 725-726 describes using histopathology results); and wherein the Al model refines the characterization of the segmented region of interest based on the accessed non-imaging patient data (page 27, lines 745-748). Regarding claim 12: Gheorghe discloses the system of claim 7, wherein the method further comprises generating, based on the characterization of the segmented region of interest, a recommendation for further procedures to be conducted on the segmented region of interest based on the characterization of the segmented region of interest (page 27, line 765 to page 28, line 781 describes using the method for determining feasibility of various treatment options). Regarding claim 13: Gheorghe discloses a non-transitory computer-readable media have instructions stored thereon that, when executed by one or more computer processors, cause the one or more processors to perform a method (detection system 100 including computer system 101, EUS system 102, interface module 104, etc. for performing the method; FIG. 1; page 4, line 103-page 6, line 153; Artificial Intelligence and Machine Learning enabled systems and methods for detecting, marking, and differentiating pancreatic lesions and pancreatic parts from endoscopic images; Abstract) comprising: receiving, at a computing device (page 4, lines 104-107; FIGS. 1 and 8), a real-time endoscopic ultrasound (EUS) video stream of a pancreas of a patient (page 24, lines 678-682), wherein the EUS video stream comprises a plurality of imaging modalities including at least grey-scale data (page 24, lines 678-682) and elastography data representing tissue stiffness (page 24, lines 678-682); processing, by one or more processors using an artificial intelligence (Al) model (page 25, lines 691-694), the EUS video stream to: identify a region of interest within the pancreas (page 22, lines 601-608); segment the identified region of interest from surrounding tissue (page 23, lines 647-652); and generate a characterization of the segmented region of interest based on an analysis of the plurality of imaging modalities (page 28, lines 782-786), including the elastography data (page 24, lines 678-682); and generating, for display on a user interface in real-time, a visual output comprising the EUS video stream with a graphical overlay (FIG. 16; page 22, lines 601-608), wherein the graphical overlay includes a visual indicator delineating the segmented region of interest and a classification label corresponding to the generated characterization (FIG. 16; page 22, lines 601-608); Based on the provided excerpt from the patent application, here are several suggestions to improve clarity, completeness, and enforceability. Regarding claim 14: Gheorghe discloses the media of claim 13 wherein the plurality of imaging modalities further comprises one or more of color doppler data (page 23, lines 635-642 and page 24, lines 678-682), contrast-enhanced arterial phase data, or contrast-enhanced venous phase data. Regarding claim 15: Gheorghe discloses the media of claim 13, wherein the classification label indicates that the segmented region of interest is one of a solid mass, a cystic lesion, or normal tissue (page 24, lines 674-677). Regarding claim 16: Gheorghe discloses the media of claim 13, wherein processing the EUS video stream by the Al model is performed on one or more remote servers in a cloud-computing environment, and wherein the computing device receives the visual output from the one or more remote servers (page 4, lines 104-107; page 13, lines 346-349; and page 20, lines 552-557 all refer to using remote cloud servers for storage and processing of data. FIG. 3 shows cloud 310 being used to process data in a loop which has output to AI Monitor 306; FIG. 8). Regarding claim 17: Gheorghe discloses he media of claim 13, wherein the method further comprises: accessing a set of non-imaging patient data from an electronic medical record, the non- imaging patient data comprising at least one of laboratory test results, genomic data, or pathology reports (page 26, lines 725-726 describes using histopathology results); and wherein the Al model refines the characterization of the segmented region of interest based on the accessed non-imaging patient data (page 27, lines 745-748). Regarding claim 18: Gheorghe discloses the media of claim 13, wherein the method further comprises generating, based on the characterization of the segmented region of interest, a recommendation for further procedures to be conducted on the segmented region of interest based on the characterization of the segmented region of interest (page 27, line 765 to page 28, line 781 describes using the method for determining feasibility of various treatment options). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CAROLYN A PEHLKE whose telephone number is (571)270-3484. The examiner can normally be reached 9:00am - 5:00pm (Central Time), Monday - Friday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Chris Koharski can be reached at (571) 272-7230. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CAROLYN A PEHLKE/Primary Examiner, Art Unit 3799
Read full office action

Prosecution Timeline

Jan 20, 2026
Application Filed
Sep 16, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12773175
Method for Generation Multi-Modality Image and Electronic Device
1y 12m to grant Granted Oct 27, 2026
Patent 12758173
VASCULAR IMAGING METHODS, SYSTEMS, AND MEDIUMS
1y 10m to grant Granted Oct 13, 2026
Patent 12751627
FIBER OPTIC NEEDLE PROBE
2y 8m to grant Granted Oct 06, 2026
Patent 12742842
PATIENT TABLE AND MAGNETIC RESONANCE IMAGING APPARATUS
1y 3m to grant Granted Sep 22, 2026
Patent 12733829
A SYSTEM AND METHOD FOR TISSUE ANALYSIS USING REMOTE PPG
2y 1m to grant Granted Sep 15, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
62%
Grant Probability
90%
With Interview (+28.1%)
3y 5m (~2y 7m remaining)
Median Time to Grant
Low
PTA Risk
Based on 499 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month